Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Cooperation from Govt, Insurers to Meet 80% Generic Target, Control of Long-Term Prescriptions Requested: Chuikyo Public Hearings
January 22, 2018
- MHLW OKs Dupixent, Tecentriq, Lynparza, and More
January 22, 2018
- PMDA to Promote Simplification of Documentation Required in Applications, Acceptance of Documents in Electronic Form
January 19, 2018
- Chuikyo OKs New Drug Pricing Rules for FY2018 Reform
January 18, 2018
- Huge Seller Price Slash to Hit Nexium/Takecab; Rituxan, 8 Other Brands to Face Market Expansion Re-Pricing
January 18, 2018
- Chuikyo OKs Special Re-Pricing for FY2018 Drug Price Revision, Here’s the List of Products
January 17, 2018
- MHLW Health Policy Chief Wants Pricing Reform to Prod Drug Makers’ Overseas Expansions
January 17, 2018
- Chuikyo Plans for FY2018 Fee Schedule Revision Now Up for Public Comments
January 15, 2018
- Novo’s Semaglutide Up for MHLW Panel Review Jan. 26 after Approval Hold
January 15, 2018
- MHLW Orders Label Revisions for Abilify, 4 Other APIs
January 12, 2018
- Streamlining Regulations of Pharmaceutical Affairs to Be “a Top Priority” in 2018: MHLW Pharma Bureau Chief
January 12, 2018
- MHLW Proposes Add’l Conditions for Penalty Medical Fee Cuts: Chuikyo
January 11, 2018
- Balancing Innovation and Universal Coverage Was Key in Drug Pricing Reform: Health Minister
January 10, 2018
- PMDA Chief Says Next Challenge Is to Boost Review Quality, Global Expansion Drive
January 9, 2018
- MHLW Unofficially Notified Companies of Products Eligible for New PMP: Sources
January 9, 2018
- MHLW Study Group Approves Framework for Comprehensive Guidelines on Pharmacotherapy in the Elderly
January 9, 2018
- Counterfeit Drug Panel OKs Final Report, MHLW to Issue GDP Guidelines in FY2018
December 27, 2017
- Council OKs Public Knowledge-Based Application for Diagnogreen, Valixa
December 26, 2017
- MHLW OKs Add’l Indications for Keytruda, Soliris and More
December 26, 2017
- Japan Cabinet OKs FY2018 Budget, 52.9 Billion Yen Earmarked for Urgent Drug Discovery Package
December 25, 2017
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…